• MindWalk Holdings named Zachary Maben director of antigen discovery and protein engineering as its pipeline nears preclinical efficacy studies.
• Maben joins from Arbor Biotechnologies, where he was a principal scientist; he previously held principal and senior scientist roles at Pfizer.
• Joanne Lim was appointed director of preclinical development, joining from Orum Therapeutics; she previously worked at Codiak Biosciences, Novartis.
• Shuji Sato, vice president of innovative solutions, expanded responsibilities to include oversight of the pipeline.
• Sato previously held roles at Dragonfly Therapeutics, Pfizer, Bluefin Biomedicine, Cell Signaling Technology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014746456) on October 14, 2026, and is solely responsible for the information contained therein.